Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2013Cited by 177
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementSusan Branford, Timothy P. Hughes, Soo-Young Choi et al.|Blood|2012Cited by 49